Phase 4 N=50 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
Prostate Cancer
Primary: Percent Change in Bone Mineral Density — 0.1; -2; 0.2; -2.2 Percent Change — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=59 Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period
Phenylketonuria
Primary: Percentage of Participants With at Least 30 Percent Reduction From Baseline in Blood Phenylalanine (Phe) Level — 75 Percentage of participants
Phase 4 N=115 An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Primary: Korean Version of the Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (K-ARS) Score — 11.78 Units on a scale
Phase 4 N=405 Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Patient Overall Preference — 4.75; 2.45 units on a scale — p=<0.0001
Phase 4 N=44 The Treatment of Insomnia in Patients With HIV Disease
HIV Infections · Insomnia
Primary: Response: Change in Insomnia Severity Rating Scale at 3 Months. — 0.72; -4.01 units on a scale
Phase 4 N=38 Brain Imaging of Lidoderm for Chronic Back Pain
Low Back Pain
Primary: Pain Intensity on a Visual Analog Scale (VAS) The Scale Had Values From 0-100, Where 0 Represents "no Pain" and 100 Was the "Worst Pain Imaginable". — 51.0; 51.6 peak…
Phase 4 N=19 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury.
Spinal Cord Injury · Pain
Primary: Numerical Rating Scale-NRS — 4.50; 3.44 units on a scale — p=0.432
Phase 4 N=276 Aminotransferase Trends During Prolonged Acetaminophen Dosing
Drug Toxicity · Healthy
Primary: The Proportion of Subjects Treated With Long-term Acetaminophen (4 g/Day) That Develops Persistent ALT Elevations. — 204; 47; 1; 0 participants
Phase 4 N=80 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale
Phase 4 N=53 Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia
Schizophrenia
Primary: Positive and Negative Syndromes Scale (PANSS) Total Score at Week 2 — 55.53 Units on a scale
Phase 4 N=60 Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Adult Attention Deficit Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) Total Score at Week 4 — 52.6; -10.9 Unit on a scale
Phase 4 N=40 A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy
Diabetic Neuropathy
Primary: Assessing the Change in Resting Blood Pressure Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy. — -7.63; -8.98; -4.41; -4.93…
Phase 4 N=81 Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
Restless Legs Syndrome
Primary: Change From Baseline in the Number of Elevations of Systolic Blood Pressure (BP) During the Night That Are Associated With Periodic Limb Movements (PLMs) at the End of…
Phase 4 N=20 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE
Hereditary Angioedema
Primary: Number of Subjects With Adverse Events, Hospitalizations, Thrombotic Events, Treatment-emergent C1 INH Antibodies, Post-baseline Toxicity Grade Increases in Clinical…
Phase 4 N=21 Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms
Seasonal Allergic Rhinitis
Primary: Total Eye Symptoms Score Difference — 6; 0; 2.5; 1.5 units on a scale — p=<0.001